Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTA018 · 2 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| CTA018 Injection low dose | EXPERIMENTAL | Low dose IV 3 times a week for 4 weeks |
| CTA018 Injection low to mid dose | EXPERIMENTAL | low to mid dose IV 3 times a week for 4 weeks |
| CTA018 Injection mid to high dose | EXPERIMENTAL | mid to high dose IV 3 times a week for 4 weeks |
| CTA018 Injection high dose | EXPERIMENTAL | high dose IV 3 times a week for 4 weeks |
| Name | Type | Description |
|---|---|---|
| CTA018 Injection | DRUG | Comparison of different dosages of drug |
| CTA018 cream | DRUG | - |
Inclusion Criteria: * Body mass index between 18 and 35 * On maintenance hemodialysis three times per week * Serum iPTH value greater than or equal to 300 pg/mL and lower than or equal to 1000 pg/mL * Adjusted or total serum calcium value greater than or equal to 8.4 mg/dL and lower than 10.0 mg/dL...
Top 20 of 25 competitors
CTA018 is an investigational small molecule being developed by Opko Health Inc. for chronic kidney disease and psoriasis. It has been studied in Phase 2 clinical trials for plaque psoriasis and for stage 5 chronic kidney disease with secondary hyperparathyroidism.
CTA018 is a small molecule developed by Opko Health Inc. Its molecular target has not been disclosed in the available information. It is being studied for chronic kidney disease and psoriasis, but its specific mechanism of action is not publicly detailed.
CTA018 is being developed by Opko Health Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol OPK. The company has conducted Phase 2 clinical trials for this investigational drug in chronic kidney disease and psoriasis.
CTA018 is in Phase 2 clinical development. It has completed two Phase 2 trials, one for plaque psoriasis and one for stage 5 chronic kidney disease. The drug is investigational and has not been approved by the FDA.
CTA018 has completed two Phase 2 trials. NCT00384098 studied topically applied CTA018 in plaque psoriasis with 140 participants in the United States. NCT00742716 studied CTA018 injection for stage 5 chronic kidney disease with 41 participants in the United States and Canada.
CTA018 is the primary name for this investigational drug developed by Opko Health Inc. No alternative names have been reported in the available clinical trial information. It is being studied for chronic kidney disease and psoriasis.